U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976177) titled 'Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis' on May 08.
Brief Summary: This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013 after treatment.The treatment duration for Part A MAD study is 52 weeks and the duration for Part B study is 26 weeks.
Study Start Date: June 07, 2024
Study Type: INTERVENTIONAL
Condition:
Secondary Hyperparathyroidism (SHPT) in ...